GSK and Cambridge University in research collaboration

Thursday 24 July 2008

GlaxoSmithKline has signed its first ever research agreement with the University of Cambridge in the UK to develop a novel, centrally-acting agent with therapeutic potential for obesity and addictive disorders. Financial terms were not disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom